[{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"||1-phosphatidylinositol 3-phosphate 5-kinase","graph1":"Neurology","graph2":"Preclinical","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kintai Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kintai Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ascentage Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ Undisclosed"},{"orgOrder":0,"company":"Enterome","sponsor":"The Institute for Follicular Lymphoma Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Financing","leadProduct":"EO2463","moa":"||B-cell activating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Enterome \/ The Institute for Follicular Lymphoma Innovation","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/ The Institute for Follicular Lymphoma Innovation"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||B-cell antigen receptor complex-associated protein beta chain | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sio Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sio Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"National Human Genome Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sio Gene Therapies \/ National Human Genome Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ National Human Genome Research Institute"},{"orgOrder":0,"company":"Overland ADCT BioPharma","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Loncastuximab Tesirine","moa":"||B-lymphocyte antigen CD19 | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Overland ADCT BioPharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Overland ADCT BioPharma \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Overland ADCT BioPharma \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||B-lymphocyte antigen CD19 | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||B-lymphocyte antigen CD19 | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||B-lymphocyte antigen CD19 | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Overland Pharmaceuticals"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||B-lymphocyte antigen CD19 | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||B-lymphocyte antigen CD19 | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||B-lymphocyte antigen CD19 | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||B-lymphocyte antigen CD19 | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||B-lymphocyte antigen CD19 | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ADC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Probiomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"MEXICO","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Probiomed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Probiomed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Probiomed \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Tours \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Tours \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Tours \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Tours \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chinese SLE Treatment And Research Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chinese SLE Treatment And Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Beijing Tongren Hospital | Chinese Academy of Medical Sciences, Fuwai Hospital | The Luhe Teaching Hospital of the Capital Medical University | The Seventh Affiliated Hospital of Sun Yat-sen University | First Affiliated Hospital of Xinjiang Medical Unive","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Beijing Tongren Hospital | Chinese Academy of Medical Sciences, Fuwai Hospital | The Luhe Teaching Hospital of the Capital Medical University | The Seventh Affiliated Hospital of Sun Yat-sen University | First Affiliated Hospital of Xinjiang Medical Unive","highestDevelopmentStatusID":"10","companyTruncated":"Peking Union Medical College Hospital \/ Beijing Tongren Hospital | Chinese Academy of Medical Sciences, Fuwai Hospital | The Luhe Teaching Hospital of the Capital Medical University | The Seventh Affiliated Hospital of Sun Yat-sen University | First Affiliated Hospital of Xinjiang Medical Unive"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Nagoya University","sponsor":"Japan Agency for Medical Research and Development | Zenyaku Kogyo","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Phase II","graph3":"Nagoya University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nagoya University \/ Japan Agency for Medical Research and Development | Zenyaku Kogyo","highestDevelopmentStatusID":"8","companyTruncated":"Nagoya University \/ Japan Agency for Medical Research and Development | Zenyaku Kogyo"},{"orgOrder":0,"company":"University of Tokyo","sponsor":"Japan Agency for Medical Research and Development | Zenyaku Kogyo","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University of Tokyo","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Tokyo \/ Japan Agency for Medical Research and Development | Zenyaku Kogyo","highestDevelopmentStatusID":"9","companyTruncated":"University of Tokyo \/ Japan Agency for Medical Research and Development | Zenyaku Kogyo"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ PPD"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Parexel"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"ZENOAQ","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"ZENOAQ","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ZENOAQ \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"ZENOAQ \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Undisclosed","graph2":"Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Severance Hospital | GC Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Severance Hospital | GC Biopharma","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Severance Hospital | GC Biopharma"},{"orgOrder":0,"company":"GC Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Cell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"University of Ulm","sponsor":"X-act Cologne Clinical Research GmbH | Center for Clinical Studies Ulm | Merck & Co | Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Ulm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Ulm \/ X-act Cologne Clinical Research GmbH | Center for Clinical Studies Ulm | Merck & Co | Celltrion","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulm \/ X-act Cologne Clinical Research GmbH | Center for Clinical Studies Ulm | Merck & Co | Celltrion"},{"orgOrder":0,"company":"University Hospital Freiburg","sponsor":"German Federal Ministry of Education and Research | International Extranodal Lymphoma Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"University Hospital Freiburg","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Freiburg \/ German Federal Ministry of Education and Research | International Extranodal Lymphoma Study Group","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital Freiburg \/ German Federal Ministry of Education and Research | International Extranodal Lymphoma Study Group"},{"orgOrder":0,"company":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","sponsor":"Bristol Myers Squibb | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH \/ Bristol Myers Squibb | Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH \/ Bristol Myers Squibb | Amgen Inc"},{"orgOrder":0,"company":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Arbeitsgemeinschaft medikament\u00f6se Tumortherapie \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University of Giessen","sponsor":"Heidelberg University | German Cancer Research Center | Astellas Pharma | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"University of Giessen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Giessen \/ Heidelberg University | German Cancer Research Center | Astellas Pharma | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Giessen \/ Heidelberg University | German Cancer Research Center | Astellas Pharma | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Nordic Lymphoma Group","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Nordic Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Lymphoma Group \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Nordic Lymphoma Group \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nordic Lymphoma Group","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Nordic Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Lymphoma Group \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Nordic Lymphoma Group \/ Amgen Inc"},{"orgOrder":0,"company":"Nordic Lymphoma Group","sponsor":"Helsinki University Central Hospital | Aarhus University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Nordic Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Lymphoma Group \/ Helsinki University Central Hospital | Aarhus University Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Nordic Lymphoma Group \/ Helsinki University Central Hospital | Aarhus University Hospital"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"French Vasculitis Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ French Vasculitis Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ French Vasculitis Study Group"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"French Vasculitis Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ French Vasculitis Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ French Vasculitis Study Group"},{"orgOrder":0,"company":"French Innovative Leukemia Organisation","sponsor":"Lymphoma Study Association | Janssen-Cilag | Mundipharma | F. Hoffmann-La Roche | Chugai Pharma Europe","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"French Innovative Leukemia Organisation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"French Innovative Leukemia Organisation \/ Lymphoma Study Association | Janssen-Cilag | Mundipharma | F. Hoffmann-La Roche | Chugai Pharma Europe","highestDevelopmentStatusID":"8","companyTruncated":"French Innovative Leukemia Organisation \/ Lymphoma Study Association | Janssen-Cilag | Mundipharma | F. Hoffmann-La Roche | Chugai Pharma Europe"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University Hospital, Limoges","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"University Hospital, Limoges","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Limoges \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital, Limoges \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University Hospital, Bordeaux","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"University Hospital, Bordeaux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Bordeaux \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Bordeaux \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ GSK"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Hematology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"French Vasculitis Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ French Vasculitis Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ French Vasculitis Study Group"},{"orgOrder":0,"company":"French Innovative Leukemia Organisation","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"French Innovative Leukemia Organisation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"French Innovative Leukemia Organisation \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"French Innovative Leukemia Organisation \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"French Innovative Leukemia Organisation","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"French Innovative Leukemia Organisation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"French Innovative Leukemia Organisation \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"French Innovative Leukemia Organisation \/ Amgen Inc"},{"orgOrder":0,"company":"Fondazione Italiana Linfomi","sponsor":"Johnson & Johnson Innovative Medicine | Janssen-Cilag | Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fondazione Italiana Linfomi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fondazione Italiana Linfomi \/ Johnson & Johnson Innovative Medicine | Janssen-Cilag | Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte","highestDevelopmentStatusID":"9","companyTruncated":"Fondazione Italiana Linfomi \/ Johnson & Johnson Innovative Medicine | Janssen-Cilag | Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte"},{"orgOrder":0,"company":"Northern Italy Leukemia Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Northern Italy Leukemia Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northern Italy Leukemia Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Northern Italy Leukemia Group \/ Undisclosed"},{"orgOrder":0,"company":"Sint Maartenskliniek","sponsor":"Dutch Arthritis Association | ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sint Maartenskliniek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sint Maartenskliniek \/ Dutch Arthritis Association | ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Sint Maartenskliniek \/ Dutch Arthritis Association | ZonMw"},{"orgOrder":0,"company":"Sint Maartenskliniek","sponsor":"ZonMw | Dutch Arthritis Association","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sint Maartenskliniek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sint Maartenskliniek \/ ZonMw | Dutch Arthritis Association","highestDevelopmentStatusID":"10","companyTruncated":"Sint Maartenskliniek \/ ZonMw | Dutch Arthritis Association"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Dutch Kidney Foundation | ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Dutch Kidney Foundation | ZonMw","highestDevelopmentStatusID":"8","companyTruncated":"Leiden University Medical Center \/ Dutch Kidney Foundation | ZonMw"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Norwegian Cancer Society | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oslo University Hospital \/ Norwegian Cancer Society | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ Norwegian Cancer Society | Merck & Co"},{"orgOrder":0,"company":"International Extranodal Lymphoma Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"International Extranodal Lymphoma Study Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"International Extranodal Lymphoma Study Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Extranodal Lymphoma Study Group \/ Undisclosed"},{"orgOrder":0,"company":"International Extranodal Lymphoma Study Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"International Extranodal Lymphoma Study Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"International Extranodal Lymphoma Study Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"International Extranodal Lymphoma Study Group \/ Undisclosed"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Arthritis Research UK | F. Hoffmann-La Roche | Genentech | University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Arthritis Research UK | F. Hoffmann-La Roche | Genentech | University of Pennsylvania","highestDevelopmentStatusID":"10","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Arthritis Research UK | F. Hoffmann-La Roche | Genentech | University of Pennsylvania"},{"orgOrder":0,"company":"Guy's and St Thomas' NHS Foundation Trust","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Guy's and St Thomas' NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guy's and St Thomas' NHS Foundation Trust \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Guy's and St Thomas' NHS Foundation Trust \/ Astellas Pharma"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lymphoma Academic Research Organisation \/ Celgene Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Lymphoma Academic Research Organisation \/ Celgene Corporation"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lymphoma Academic Research Organisation \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Lymphoma Academic Research Organisation \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"University College, London","sponsor":"Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College, London \/ Janssen-Cilag","highestDevelopmentStatusID":"9","companyTruncated":"University College, London \/ Janssen-Cilag"},{"orgOrder":0,"company":"University Hospital Southampton NHS Foundation Trust","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"University Hospital Southampton NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Southampton NHS Foundation Trust \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Southampton NHS Foundation Trust \/ AstraZeneca"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lymphoma Academic Research Organisation \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Lymphoma Academic Research Organisation \/ Pfizer Inc"},{"orgOrder":0,"company":"German CLL Study Group","sponsor":"Janssen-Cilag | F. Hoffmann-La Roche | AbbVie Inc | Stichting Hemato-Oncologie voor Volwassenen Nederland | Nordic CLL Study Group | Swiss Group for Clinical Cancer Research | Cancer Trials Ireland | Israeli CLL Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"German CLL Study Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German CLL Study Group \/ Janssen-Cilag | F. Hoffmann-La Roche | AbbVie Inc | Stichting Hemato-Oncologie voor Volwassenen Nederland | Nordic CLL Study Group | Swiss Group for Clinical Cancer Research | Cancer Trials Ireland | Israeli CLL Study Group","highestDevelopmentStatusID":"10","companyTruncated":"German CLL Study Group \/ Janssen-Cilag | F. Hoffmann-La Roche | AbbVie Inc | Stichting Hemato-Oncologie voor Volwassenen Nederland | Nordic CLL Study Group | Swiss Group for Clinical Cancer Research | Cancer Trials Ireland | Israeli CLL Study Group"},{"orgOrder":0,"company":"Universit\u00e4t des Saarlandes","sponsor":"University of Leipzig | University Hospital Regensburg | Wuerzburg University Hospital | University Hospital Giessen and Marburg | Saarland University Medical Center | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Universit\u00e4t des Saarlandes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e4t des Saarlandes \/ University of Leipzig | University Hospital Regensburg | Wuerzburg University Hospital | University Hospital Giessen and Marburg | Saarland University Medical Center | AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Universit\u00e4t des Saarlandes \/ University of Leipzig | University Hospital Regensburg | Wuerzburg University Hospital | University Hospital Giessen and Marburg | Saarland University Medical Center | AstraZeneca"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Mabion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabion SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Undisclosed"},{"orgOrder":0,"company":"Mabion SA","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabion SA \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Parexel"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Genentech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Genentech"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"||B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Mabxience","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Mabxience \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Nordic Lymphoma Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Nordic Lymphoma Group","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Nordic Lymphoma Group"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Karolinska Institutet | Ohio State University | Dutch Working Party on Systemic Lupus Erythematosus | EULAR Lupus Nephritis Trial Network Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imperial College London \/ Karolinska Institutet | Ohio State University | Dutch Working Party on Systemic Lupus Erythematosus | EULAR Lupus Nephritis Trial Network Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Imperial College London \/ Karolinska Institutet | Ohio State University | Dutch Working Party on Systemic Lupus Erythematosus | EULAR Lupus Nephritis Trial Network Study Group"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Hexal AG","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sandoz B2B \/ Hexal AG","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Hexal AG"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Mabion SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabion SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Mashhad University of Medical Sciences","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase IV","graph3":"Mashhad University of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mashhad University of Medical Sciences \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"11","companyTruncated":"Mashhad University of Medical Sciences \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Leumit Health Services","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Undisclosed","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Leumit Health Services","highestDevelopmentStatusID":"1","companyTruncated":"Rabin Medical Center \/ Leumit Health Services"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Davis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Davis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Rocky Mountain MS Research Group, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Colorado, Denver \/ Rocky Mountain MS Research Group, LLC","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ Rocky Mountain MS Research Group, LLC"},{"orgOrder":0,"company":"Northside Hospital","sponsor":"Blood and Marrow Transplant Group of Georgia","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Northside Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northside Hospital \/ Blood and Marrow Transplant Group of Georgia","highestDevelopmentStatusID":"8","companyTruncated":"Northside Hospital \/ Blood and Marrow Transplant Group of Georgia"},{"orgOrder":0,"company":"Northside Hospital","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Northside Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northside Hospital \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Northside Hospital \/ Pharmacyclics"},{"orgOrder":0,"company":"Eastern Cooperative Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Eastern Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eastern Cooperative Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Eastern Cooperative Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Alliance for Clinical Trials in Oncology","sponsor":"National Cancer Institute | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Alliance for Clinical Trials in Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | Celgene Corporation"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Hospital for Special Surgery, New York","sponsor":"Genentech | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Rare Diseases and Disorders","graph2":"Phase IV","graph3":"Hospital for Special Surgery, New York","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital for Special Surgery, New York \/ Genentech | F. Hoffmann-La Roche","highestDevelopmentStatusID":"11","companyTruncated":"Hospital for Special Surgery, New York \/ Genentech | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Duke University","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Duke University \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Nationwide Children\u2019s Hospital","sponsor":"Gabrail Cancer Center Research | Children's Healthcare of Atlanta | Genentech | NephCure Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Nationwide Children\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nationwide Children\u2019s Hospital \/ Gabrail Cancer Center Research | Children's Healthcare of Atlanta | Genentech | NephCure Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Nationwide Children\u2019s Hospital \/ Gabrail Cancer Center Research | Children's Healthcare of Atlanta | Genentech | NephCure Foundation"},{"orgOrder":0,"company":"Radiation Therapy Oncology Group","sponsor":"National Cancer Institute | NRG Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Pharmacology\/Toxicology","graph2":"Phase II","graph3":"Radiation Therapy Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiation Therapy Oncology Group \/ National Cancer Institute | NRG Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Radiation Therapy Oncology Group \/ National Cancer Institute | NRG Oncology"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fox Chase Cancer Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Fox Chase Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Brown University","sponsor":"Spectrum Pharmaceuticals | Rhode Island Hospital | The Miriam Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Spectrum Pharmaceuticals | Rhode Island Hospital | The Miriam Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Brown University \/ Spectrum Pharmaceuticals | Rhode Island Hospital | The Miriam Hospital"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCRI Development Innovations, LLC \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"SCRI Development Innovations, LLC \/ Genentech"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Celgene Corporation"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Pharmacyclics"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"MD Anderson Cancer Center \/ Genentech"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Genentech"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Autoimmunity Centers of Excellence | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Autoimmunity Centers of Excellence | Rho, Inc"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"University Health Network, Toronto | National Institutes of Health | Genentech | Rush University Medical Center | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mayo Clinic \/ University Health Network, Toronto | National Institutes of Health | Genentech | Rush University Medical Center | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ University Health Network, Toronto | National Institutes of Health | Genentech | Rush University Medical Center | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mayo Clinic \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Genentech"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aptevo Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Divestment","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Aptevo Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Comera Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Comera Life Sciences \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Comera Life Sciences \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Columbia University | University of British Columbia | Ohio State University | Stanford University | University of Washington | University of Michigan | University of Alabama at Birmingham | Case Western Reserve University | Cleveland Clinic | University ","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Columbia University | University of British Columbia | Ohio State University | Stanford University | University of Washington | University of Michigan | University of Alabama at Birmingham | Case Western Reserve University | Cleveland Clinic | University ","highestDevelopmentStatusID":"9","companyTruncated":"Mayo Clinic \/ Columbia University | University of British Columbia | Ohio State University | Stanford University | University of Washington | University of Michigan | University of Alabama at Birmingham | Case Western Reserve University | Cleveland Clinic | University "},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Celgene Corporation"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Lymphoma Academic Research Organisation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Lymphoma Academic Research Organisation","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Lymphoma Academic Research Organisation"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"National Heart, Lung, and Blood Institute | Clinical Trials in Organ Transplantation | Genentech | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Heart, Lung, and Blood Institute | Clinical Trials in Organ Transplantation | Genentech | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Heart, Lung, and Blood Institute | Clinical Trials in Organ Transplantation | Genentech | Rho, Inc"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Clinical Trials in Organ Transplantation in Children | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation in Children | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation in Children | Rho, Inc"},{"orgOrder":0,"company":"Columbia University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Genentech"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"National Institutes of Health | National Cancer Institute | Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Presage Biosciences \/ National Institutes of Health | National Cancer Institute | Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ National Institutes of Health | National Cancer Institute | Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"iBio","sponsor":"Azargen Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iBio \/ Azargen Biotechnologies","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Azargen Biotechnologies"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juno Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Peter MacCallum Cancer Centre","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peter MacCallum Cancer Centre","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peter MacCallum Cancer Centre \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Peter MacCallum Cancer Centre \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Australasian Leukaemia & Lymphoma Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Undisclosed","graph3":"Australasian Leukaemia & Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Australasian Leukaemia & Lymphoma Group \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Australasian Leukaemia & Lymphoma Group \/ Merck & Co"},{"orgOrder":0,"company":"Diako","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Diako","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Diako \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Diako \/ Undisclosed"},{"orgOrder":0,"company":"Mabscale","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Mabscale","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabscale \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabscale \/ Undisclosed"},{"orgOrder":0,"company":"Biointegrator","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Biointegrator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biointegrator \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biointegrator \/ Undisclosed"},{"orgOrder":0,"company":"Prof. Dr. M. Dreyling (co-chairman)","sponsor":"Klinikum der Universit\u00e4t M\u00fcnchen | ClinAssess | GELARC Service de Pharmacovigilance, Pierre Benite","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Prof. Dr. M. Dreyling (co-chairman)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prof. Dr. M. Dreyling (co-chairman) \/ Klinikum der Universit\u00e4t M\u00fcnchen | ClinAssess | GELARC Service de Pharmacovigilance, Pierre Benite","highestDevelopmentStatusID":"10","companyTruncated":"Prof. Dr. M. Dreyling (co-chairman) \/ Klinikum der Universit\u00e4t M\u00fcnchen | ClinAssess | GELARC Service de Pharmacovigilance, Pierre Benite"},{"orgOrder":0,"company":"Gustave Roussy","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Gustave Roussy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gustave Roussy \/ Children's Oncology Group","highestDevelopmentStatusID":"10","companyTruncated":"Gustave Roussy \/ Children's Oncology Group"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":3.7000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":3.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":3.7000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":3.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"CSL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Undisclosed"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL \/ ChemoCentryx","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ ChemoCentryx"},{"orgOrder":0,"company":"CSL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ MorphoSys"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"||CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"||CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Letaplimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Ontorpacept","moa":"||CD47\/CD64","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Glucocorticoid","moa":"||CLDN1","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GlucoCorticoid","moa":"||CLDN1","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Chidamide","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Antengene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Selinexor","moa":"||Exportin-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Antengene \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Cancer Research"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"SkylineDx","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I","graph3":"SkylineDx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SkylineDx \/ BioInvent","highestDevelopmentStatusID":"6","companyTruncated":"SkylineDx \/ BioInvent"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"BioInvent","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BI-1206","moa":"||Fc-gammaRllb","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharmaceuticals \/ BioInvent"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Henlius","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Licensing Agreement","leadProduct":"Bi-Sialidase","moa":"||Glyco-immune checkpoint","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Henlius","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Pharmaceuticals \/ Henlius"},{"orgOrder":0,"company":"Epizyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Undisclosed"},{"orgOrder":0,"company":"Epizyme","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Undisclosed"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Naratuximab Emtansine","moa":"||Leukocyte antigen CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Debiopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm \/ Undisclosed"},{"orgOrder":0,"company":"Nucleai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Naratuximab Emtansine","moa":"||Leukocyte antigen CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nucleai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nucleai \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nucleai \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncology \/ Undisclosed"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"||Methotrexate","graph1":"Oncology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BTG Specialty Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specialty Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyteir Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rad51-IN-2","moa":"||Monocarboxylate transporter","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyteir Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Neurotrophic tyrosine kinase ROR1 (ROR1)","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Nephrology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Merus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Parsaclisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Merus","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Merus"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MEI Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Qiagen","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Enzastaurin","moa":"||Protein kinase C beta","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qiagen \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ Denovo Biopharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"||SIRPA","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"||SIRPA","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ AbbVie Inc"},{"orgOrder":0,"company":"Genmab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Genmab \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Seagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Acerta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Acerta Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Acerta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Acerta Pharma"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Loxo-305","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loxo Oncology Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncology Inc \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Orelabrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zanubrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 t-haNK","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"EMERCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"OT-C001","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onward Therapeutics \/ Emercell","highestDevelopmentStatusID":"5","companyTruncated":"Onward Therapeutics \/ Emercell"},{"orgOrder":0,"company":"PolTREG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"PTG-007","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PolTREG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Undisclosed"},{"orgOrder":0,"company":"PolTREG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"PTG-007","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PolTREG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Undisclosed"},{"orgOrder":0,"company":"PolTREG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"PTG-007","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PolTREG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Undisclosed"},{"orgOrder":0,"company":"PolTREG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"PTG-007","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PolTREG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Undisclosed"},{"orgOrder":0,"company":"PolTREG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"POLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"PTG-007","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"PolTREG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolTREG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolTREG \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Neufeld, Ellis J, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Neufeld, Ellis J, MD, PhD","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Neufeld, Ellis J, MD, PhD"},{"orgOrder":0,"company":"Genentech","sponsor":"Stephen Howell, M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Stephen Howell, M.D.","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Stephen Howell, M.D."},{"orgOrder":0,"company":"Genentech","sponsor":"George W. Burke","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ George W. Burke","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ George W. Burke"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Joseph Tuscano","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectrum Pharmaceuticals \/ Joseph Tuscano","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum Pharmaceuticals \/ Joseph Tuscano"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Georg Hess","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Georg Hess","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Georg Hess"},{"orgOrder":0,"company":"Celltrion","sponsor":"Won Seog Kim","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Won Seog Kim","highestDevelopmentStatusID":"8","companyTruncated":"Celltrion \/ Won Seog Kim"},{"orgOrder":0,"company":"Celltrion","sponsor":"Kim Seok Jin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Kim Seok Jin","highestDevelopmentStatusID":"8","companyTruncated":"Celltrion \/ Kim Seok Jin"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Xiaohui He","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Xiaohui He","highestDevelopmentStatusID":"8","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Xiaohui He"},{"orgOrder":0,"company":"Genentech","sponsor":"Stanley Jordan, MD","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Stanley Jordan, MD","highestDevelopmentStatusID":"7","companyTruncated":"Genentech \/ Stanley Jordan, MD"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Tatsuo Kawai, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Nephrology","graph2":"Phase I","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eledon Pharmaceuticals \/ Tatsuo Kawai, MD, PhD","highestDevelopmentStatusID":"6","companyTruncated":"Eledon Pharmaceuticals \/ Tatsuo Kawai, MD, PhD"}]

Find Clinical Drug Pipeline Developments & Deals for RITUXAN

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Tepkinly (epcoritamab) is an IgG1-bispecific antibody, which is evaluated for the treatment of diffuse large B-cell lymphoma. It is designed to direct cytotoxic T cells selectively.

                          Product Name : Tepkinly

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          December 09, 2024

                          Lead Product(s) : Epcoritamab,Cyclophosphamide,Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          02

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Ituxredi (rituximab) is an anti-CD20 monoclonal antibody, which is indicated for the treatment of non-hodgkin’s lymphoma, chronic lymphocytic leukemia & rheumatoid arthritis.

                          Product Name : Ituxredi

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          July 29, 2024

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          03

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : DRL_RI is being developed as a biosimilar of Rituxan/MabThera (rituximab), a CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, ...

                          Product Name : Ituxredi

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          July 12, 2023

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          04

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : DRL_RI is being developed as a biosimilar of rituximab, CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, pemphigus vulgaris et...

                          Product Name : Ituxredi

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          January 19, 2023

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          05

                          Details : Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM.

                          Product Name : Imbruvica

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 23, 2020

                          Lead Product(s) : Ibrutinib,Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          06

                          Details : Phase 3 MURANO trial shows median progression-free survival of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in combination with rituximab Vs. 17.0 months in patients taking bendamustine plus rituximab after three years or mor...

                          Product Name : Venclexta

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 05, 2020

                          Lead Product(s) : Venetoclax,Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          07

                          Details : Submission is based on results of more than five years of follow-up data from the Phase 3 iNNOVATE clinical trial evaluating IMBRUVICA in combination with rituximab for patients with WM. This is the longest follow-up data available for a BTK inhibitor in...

                          Product Name : Imbruvica

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 23, 2020

                          Lead Product(s) : Ibrutinib,Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          08

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : PPD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Rituximab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          February 13, 2020

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : PPD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          09

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Parexel

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Rituximab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, Follicular.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          June 05, 2019

                          Lead Product(s) : Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Parexel

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          10

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Monjuvi (tafasitamab) in combination with rituximab and lenalidomide is approved for patients with relapsed or refractory follicular lymphoma.

                          Product Name : Monjuvi

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          June 18, 2025

                          Lead Product(s) : Tafasitamab,Lenalidomide,Rituximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank